share_log

Truist Securities Maintains Buy on Cormedix, Lowers Price Target to $12

Benzinga ·  Jul 25 10:32  · Ratings

Truist Securities analyst Joon Lee maintains Cormedix (NASDAQ:CRMD) with a Buy and lowers the price target from $14 to $12.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment